Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.48 |
| ▸ | JAK2 | O60674 | 3/20 | 0.48 |
| ▸ | JAK3 | P52333 | 3/20 | 0.48 |
| ▸ | BLK | P51451 | 2/20 | 0.48 |
| ▸ | BMX | P51813 | 2/20 | 0.48 |
| ▸ | CTSC | P53634 | 4/20 | 0.46 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.45 |
| ▸ | NUAK2 | Q9H093 | 2/20 | 0.45 |
| ▸ | BTK | Q06187 | 3/20 | 0.44 |
| ▸ | PLK4 | O00444 | 1/20 | 0.44 |
| ▸ | GAK | O14976 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.44 |
| ▸ | ITK | Q08881 | 1/20 | 0.44 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.44 |
| ▸ | DCLK3 | Q9C098 | 1/20 | 0.44 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.44 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24392962 | 1.00 | EGFR (0.48) | EGFRJAK2JAK3BLKBMX | |
| SCHEMBL24392961 | 0.84 | EGFR (0.51) | EGFRJAK2JAK3BLKBMX | |
| SCHEMBL29537062 | 0.84 | EGFR (0.51) | EGFRJAK2JAK3BLKBMX | |
| SCHEMBL4171563 | 0.83 | EGFR (0.48) | EGFRJAK2JAK3BLKBMX | |
| SCHEMBL9945483 | 0.83 | EGFR (0.43) | EGFRITK | |
| SCHEMBL13166463 | 0.82 | SYK (0.51) | EGFRBTKITK | |
| SCHEMBL4175660 | 0.82 | EGFR (0.45) | EGFRBTKFLT3 | |
| SCHEMBL29537718 | 0.82 | EGFR (0.45) | EGFRBTKFLT3 | |
| SCHEMBL4166321 | 0.80 | EGFR (0.49) | EGFRBTKKDR | |
| SCHEMBL29250596 | 0.79 | PIN1 (0.41) | EGFRJAK2JAK3BLKBMX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240051945-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | BLUEPRINT MEDICINES CORPORATION | 2024-02-15 | — | — | US | disclosed |
| EP-4237418-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | Blueprint Medicines Corporation (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022094354-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | LENGO THERAPEUTICS, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240051945-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | TYMP, DPYD, TYMS | EGFR 4504/4885JAK2 1372/4885JAK3 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.